Home » Stocks » Ocugen

Ocugen, Inc. (OCGN)

Stock Price: $0.518 USD -0.012 (-2.30%)
Updated Aug 4, 2020 12:30 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 69.91M
Revenue (ttm) n/a
Net Income (ttm) -17.57M
Shares Out 135.01M
EPS (ttm) n/a
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 4, 2020
Last Price $0.518
Previous Close $0.530
Change ($) -0.012
Change (%) -2.30%
Day's Open 0.535
Day's Range 0.500 - 0.545
Day's Volume 14,019,051
52-Week Range 0.170 - 17.400

More Stats

Market Cap 69.91M
Enterprise Value 68.44M
Earnings Date (est) Nov 6, 2020
Ex-Dividend Date n/a
Shares Outstanding 135.01M
Float 60.92M
EPS (basic) n/a
EPS (diluted) n/a
FCF / Share -0.25
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 325,123
Short Ratio 0.01
Short % of Float 0.08%
Beta n/a
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 10.25
Revenue n/a
Operating Income -13.98M
Net Income -17.57M
Free Cash Flow -13.17M
Net Cash 1.47M
Net Cash / Share 0.01
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -119.20%
ROE n/a
ROIC 533.40%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (2)

Buy 1
Overweight 0
Hold 1
Underweight 0
Sell 0

Analyst Consensus: Overweight

Price Target

(88.30% upside)
Current: $0.518
Target: 0.98
*Average 12-month price target from 2 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Gross Profit-------0.03
Operating Income-14.16-16.14-24.95-30.31-31.82-32.66-16.85-14.97
Net Income-20.24-18.22-22.50-13.86-32.02-10.51-56.002.81
Shares Outstanding13.894.960.380.
Earnings Per Share-1.46-3.67-59.39-130.77-145.17-410.92-5,793.64170.97
Operating Cash Flow-16.89-11.63-23.02-25.74-30.03-17.94-15.28-12.23
Capital Expenditures-0.03-0.08-0.28-0.32-1.95-3.32-0.55-0.08
Free Cash Flow-16.92-11.71-23.30-26.06-31.98-21.26-15.84-12.31
Cash & Equivalents7.601.788.1232.0531.0558.669.2615.24
Total Debt1.418.500.180.761.341.75--
Net Cash / Debt6.19-6.727.9431.2829.7156.919.2615.24
Book Value11.02-12.71-11.2713.5728.2054.21-75.55-19.71
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Ocugen, Inc.
Country United States
Employees 16
CEO Shankar Musunuri

Stock Information

Ticker Symbol OCGN
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: OCGN


Ocugen, Inc., a clinical stage biopharmaceutical company, focuses on discovering, developing, and commercializing a pipeline of innovative therapies that address rare and underserved eye diseases. The company offers an ophthalmology portfolio that includes novel gene therapies, biologics, and small molecules, as well as targets a range of retinal and ocular surface diseases. Its pipeline includes OCU400 and OCU410 for the treatment of inherited retinal disorders; OCU200 for the treatment of wet-AMD, DME, and diabetic retinopathy; OCU100 for retinitis pigmentosa; and OCU300, which is in Phase III clinical trial for the treatment of ocular graft versus host diseases. The company has a strategic partnership with CanSino Biologics Inc. for gene therapy co-development and manufacturing. Ocugen, Inc. is based in Malvern, Pennsylvania.